TORONTO, ONTARIO--(Marketwire - Sept. 27, 2012) -
RepliCel Life Sciences Inc.'s common shares (RP) have been approved for listing on CNSX.
RepliCel is developing and patenting a new hair follicle cell replication technology that has the potential to become the first autologous cellular treatment for hair loss in men and women.
Listing and disclosure documents will be available in the Listings Disclosure Hall .
|Trading Date: Monday, October 1, 2012
|CUSIP: 76027P 10 3
|ISIN: CA 76027P 10 3 6